Diabetic Peripheral Neuropathy Global Market Report 2025

The diabetic peripheral neuropathy market size has grown strongly in recent years. It will grow from $3.51 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the expanding geriatric population, the increasing prevalence of diabetes, rising healthcare expenditure, growing awareness of diabetic complications, and the enhancement of healthcare infrastructure.

The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the rise in sedentary lifestyles, increased government initiatives and funding, the growing prevalence of neuropathy risk factors, improved diagnostic accuracy, and expanding support for early detection and prevention. Key trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, increased investment in research and development, the development of minimally invasive procedures, and a heightened focus on collaborative research and development.

The rising prevalence of obesity-related health issues is anticipated to drive the expansion of the diabetic peripheral neuropathy market in the coming years. Obesity is a medical condition characterized by excessive body fat accumulation, which can impair health and increase the risk of chronic diseases. The growing awareness of obesity-related health concerns, lifestyle changes, and the increasing need for preventive and treatment solutions have contributed to greater healthcare demand. Diabetic peripheral neuropathy plays a critical role in obesity management by offering insights into nerve damage caused by obesity-related conditions, enabling targeted interventions to enhance patient well-being and quality of life. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations focused on global public health, reported that in 2022, 43% of adults aged 18 and over were classified as overweight, while 16% were living with obesity. Additionally, 37 million children under the age of five were overweight, and among children and adolescents aged 5 to 19 years, over 390 million were overweight, including 160 million affected by obesity. As a result, the increasing incidence of obesity-related health issues is driving growth in the diabetic peripheral neuropathy market.

Leading companies in the diabetic peripheral neuropathy market are prioritizing technological advancements, such as NaV1.8 pain signal inhibitors, to offer innovative non-opioid treatments that improve pain management and enhance patients' quality of life. A NaV1.8 pain signal inhibitor is a specialized drug that blocks the NaV1.8 sodium channel, a key mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without relying on opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced progress in its suzetrigine pain program, including the initiation of a Phase 3 pivotal program for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has demonstrated promising results in earlier studies and recently received breakthrough therapy designation from the Food and Drug Administration (FDA), a US-based federal agency, for diabetic peripheral neuropathy pain management.

In December 2024, ElectroCore, Inc., a US-based medical technology company, acquired NeuroMetrix, Inc. for $26 million. This acquisition aims to expand ElectroCore’s bioelectronic health and wellness portfolio by integrating NeuroMetrix’s Quell platform. The strategic move is intended to enhance non-invasive, technology-driven solutions for managing chronic pain and addressing conditions such as diabetic peripheral neuropathy while improving technological capabilities and increasing market reach. NeuroMetrix, Inc. is a US-based healthcare company specializing in the development and commercialization of products designed to diagnose and treat diabetic peripheral neuropathy.

Major players in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.

North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic peripheral neuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetic Peripheral Neuropathy (DPN) is a nerve disorder resulting from prolonged high blood sugar levels in individuals with diabetes, causing nerve damage primarily in the legs, feet, arms, and hands. This condition develops due to long-term elevated blood sugar levels, which harm the nerves and blood vessels, leading to impaired nerve function and reduced blood flow to the affected areas.

The primary types of diabetic peripheral neuropathy include type 2 and type 1 diabetic peripheral neuropathy. Type 2 diabetic peripheral neuropathy is a nerve damage condition caused by prolonged high blood sugar levels in individuals with type 2 diabetes, resulting in pain, numbness, and tingling, mainly in the feet and hands. Treatment options encompass pain management drugs and emerging gene therapies, while therapeutic approaches involve the use of antidepressants and anticonvulsants. The affected patient population primarily consists of adult and geriatric individuals.

The diabetic peripheral neuropathy market research report is one of a series of new reports that provides diabetic peripheral neuropathy market statistics, including the diabetic peripheral neuropathy industry global market size, regional shares, competitors with the diabetic peripheral neuropathy market share, detailed diabetic peripheral neuropathy market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic peripheral neuropathy industry. This diabetic peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic peripheral neuropathy market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical treatment services, and physical and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic peripheral neuropathy market also includes sales of pharmaceuticals, medical devices, nutritional supplements, and physical therapy tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.